Reshma L. Mahtani DO

Biographical Sketch:

Dr.Reshma L. Mahtani is a medical oncologist practicing in South Florida. She is an Associate Professor of Medicine at the University of Miami, Sylvester Comprehensive Cancer Center in Deerfield Beach, Florida. She is Co-Leader of the Breast Cancer Program and Director of Community Outreach. 

After completing her master of science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship in Hematology/Oncology. She is a graduate of the Harvard Global Clinical Scholars Training Program.

Dr. Mahtani is committed to medical education. She speaks nationally and internationally and has served as Program Director for several officially licensed Best of ASCO programs.  She is an active clinical researcher and her research focuses on novel therapies for the treatment of breast cancer. As Interim Co-Leader of the Breast Cancer Program at Sylvester, she oversees the clinical trial program across the network. She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and is a member of the editorial board of The Breast Journal. 

Positions:
Co-Leader Breast Cancer Program, Sylvester Comprehensive Cancer Center, University of Miami

Associate Professor of Clinical Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, Deerfield Beach, Florida

Degrees:

DO: University of New England College of Osteopathic Medicine

MS (Neuroscience): University of Connecticut

Postgraduate Training:

Fellowship: St. Vincent’s Catholic Medical Center, New York, New York

Certificate: Harvard Global Clinical Scholars Training Program

Clinical Interests:

Breast cancer, novel therapeutics